or insufficient adjustment for confounding variables, and random error 6, 7 . The study by Joosten et al 8 is not immune to these challenges. In addition to limitations mentioned by the authors, the presence of hypertension in almost one-third of the cohort makes reverse causality and underestimation of the relationship a possibility. Sensitivity analyses that exclude early years of follow-up do not eliminate this problem. Residual confounding and difficulty identifying causality for an exposure (Na) that is highly interrelated with caloric intake and other food components are also concerns. Despite these apprehensions, the authors' attention to study design, conduct, analysis, and interpretation makes their investigation of much higher caliber than most previous reports. Only two of the preceding seven observational studies of Na and CHD were based on a larger number of CHD events 9, 10 and neither of these studies matched the capacity of the new report to minimize systematic and random error. Joosten et al did not identify an overall relationship between Na and CHD but they did observe a significant direct relationship between Na and CHD in susceptible persons with a higher level of plasma Nterminal pro-B-type naturetic peptide (NT-ProBNP) or hypertension. It seems plausible that higher levels of NT-ProBNP might serve as an indicator for individuals who are more salt sensitive 11, 12 , an entity that has been associated with an increased risk of hypertension, obesity and the metabolic syndrome 13 . The study by Joosten et al is a welcome addition to the literature as provides valuable information of higher quality regarding the relationship between Na and CHD, an important area that has been understudied.
Clinical events experience from RCT, albeit limited, is consistent with a beneficial effect of Na reduction on CVD mortality and morbidity. In a high-risk group of Taiwanese veterans, substitution of a potassium enriched salt with approximately 50% less Na was reported to result in a significant 41% reduction in CVD mortality, an increase in life expectancy and a reduction CHD were based on a larger number of CHD events 9, 10 and neither of these stud die ie ies ma ma atc tc tche he at the 18-month visit. These modest changes in Na intake resulted in a significant decrement in BP during phase I (primary trial endpoint) and a significant decrease in the incidence of hypertension during phase II (primary trial endpoint). Following completion of the trials, active and passive surveillance was employed to monitor health outcomes in both cohorts during 15 (phase 1) or 10 (phase 2) years of follow-up. In a pooled analysis of events over the entire period of observation, Na reduction was associated with a significant 30% reduction in CVD events and a non-significant 20% reduction in CVD mortality 16 . Behavior change interventions are challenging and only yield a small reduction in Na. Dose-response relationships in TOHP antihypertensive medication (primary trial endpoint) but also yielded a non-sign nif if fic c can an a t t 23 23 23% % % decrease in CVD events 15 .
In phases I and II of the Trials of Hypertension Prevention (TOHP)
31 126 26 26 p p pa ar arti ti tici ci cipa pant ts s s w w with high normal BP were ass sig ig ign ne ed to Na redu uct ct c ion n (n (n (n= =1518) or control n n= =1 1608). The e N Na N red ed duc uc cti ti tion on on i i in nt nter erve ve ven nt n i io on n ns w w wer r re co o on n nduc c cte te ed d ov ov over er 1 18 8 mo mont nt n h hs hs in in in p pha ha ase se s I I a and nd d 3 3 3-4 -4 -4 ye year ar ars s in in in p p pha ha has se se I II I, I, r r res esu ul lti ing ng n in n n si si imi mi mila la lar r n ne net t t de de dec c crea ea ease se es in in 2 2 24-4-4-ho ho hour ur r u u ur ri rina na nary ry r Na Na Na f for or or c c cor or o re re resp sp spon n ndi di ing ng tim m me A modest 4% per year decrease in Na intake might prevent more than half a million deaths and add almost two million person-years of life in the US over a period of ten years 20 . A gradual decrease in the addition of Na to food products represents the easiest "lifestyle" change for the general population and the intervention option with the greatest potential for success. This approach has already produced meaningful Na intake reductions in Finland and England, coupled with a significant decrement in population BP, stroke rates, and healthcare costs 21 . The AHA recommendation of <1500 mg/d in 99.9% of men and 98.2% of women, a an nd nd t t the he e U U US S S f Government's Dietary Guidelines for Americans recommendation of <2300 mg/d in 96.9% of me men n n an an and d d 77 77 77.6 .6 .6% of of of w women. Even in subgroups th h hou ou o g ght to be espec ec ciall ly y y se se sensitive to dietary Na 50 0 0 years, no on-n-H Hi isp pa a anic ic ic b b bla la lack ck cks, s, t t tho ho hose e e w w with h p pr rehyp yp yperte te en ns nsio io on, , h hy y yper erte ten n nsi io on, n, , d d di ia iabe be ete te tes s s or or r c c chr h hron o oni i ic ki kidn dn dney ey ey d dis isea ea ease se) ) a a alm mo mos st st e e eve very y yon on o e e e ex ex exce cee ed eded ed ed t th the e e AH AH AHA A A a an and d d U US US G G Gov ov ver er ernm nm nmen en ent t Na Na Na i i int nt n ak ak ake e e ecommenda ati ti ion on on o o of f f <1 <1 <150 5 5 0 0 mg mg mg/d d d ( ( (ra ra ang ng n e: e: e: 9 9 98. 8. 8.5% 5% 5% t to o o 9 9 99. 9. 9 7% 7% %). ). ). G G Glo lo oba ba bal me me mean an an ( ( (95 95 95% % CI CI CI) ) ) da da dail i y Na successful voluntary and mandated reformulation of food products to contain less added Na in these countries indicates that a gradual reduction in Na is feasible and acceptable. Feasibility is further underscored by the substantial variation in Na content for identical food products marketed by the same manufacturers in different countries 22 . There is, however, no evidence that the US population has benefited from a reduction in the addition of Na during food processing 23 .
Likewise, in Canada only 1% of meals served by 26 sit-down restaurant chains met the FDA criterion for a "healthy meal" (<600 mg) and the average Na content per meal was consistently in excess of the AHA and WHO daily intake guidelines for breakfast (2027 mg), lunch (2297 mg) and dinner (2297 mg) 24 . The American Heart Association, the Centers for Disease Control and Prevention, the New York City Health Department and many other federal, state and local agencies are actively engaged in initiatives to reduce Na and improve the health of the public. It remains to be seen whether these initiatives will prove to be more successful than previous attempts to reduce Na in the United States.
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